DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/vvtdz4/renal_cancer_drug) has announced the addition of the "Renal Cancer Drug Pipeline Update 2013" report to their offering.
The high existing unmet need in the treatment of renal cancer is reflected by the poor prognosis of patients with advanced stage disease, five- year survival rates with existing cytokine therapy being less than 20% (RCC) in this patient cohort. The identification of biomarkers is set to revolutionize patient staging and prognosis by individualizing patient treatments and creating novel drug targets.
There are today 166 companies plus partners developing 203 drugs targeting renal cancer in development. In addition, there are 4 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 68 drugs. Renal Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 190 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 185 out of the 187 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 51 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.
Drug Pipeline Update at a Glance
Includes more than 166 principal companies plus their collaborators. There is direct access from inside the application to web pages of all principal companies.
This Drug Pipeline Update contains 203 drugs in development for the treatment of renal cancer. In addition there are suspended and ceased drugs.
The identity of available biological structures on 147 drug targets was retrieved from the RCSB Protein Databank for you to easily review the 2541 structures available today among drug targets.
For more information visit http://www.researchandmarkets.com/research/vvtdz4/renal_cancer_drug
About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.